白云山：附属公司广州医药拟增资扩股募集10亿至30亿元

南方财经网07-10

　　南财智讯7月10日电，白云山（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。广州医药为公司持股90.92%的非全资附属公司，截至2026年3月31日，资产总额为41,232,941,749.26元，所有者权益为8,153,811,730.26元；2025年度营业收入58,168,636,893.30元，归属于母公司所有者的净利润608,522,401.14元。本次增资旨在满足业务发展资金需求，优化流动性、提升财务风险抵御能力，增强综合竞争力，不改变公司对广州医药的实际控制权。目前该事项尚处于预披露阶段，未签署交易合同，亦无履约安排，最终是否实施存在不确定性。

（文章来源：南方财经网）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2650184133?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-10 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650184133","market":"hk","top_or_hot":-1,"title":"白云山：附属公司广州医药拟增资扩股募集10亿至30亿元","media":"南方财经网","content":"<html><body><div>\n<p>　　南财智讯7月10日电，<span><a href=\"https://laohu8.com/S/600332\">白云山</a></span>（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。广州医药为公司持股90.92%的非全资附属公司，截至2026年3月31日，资产总额为41,232,941,749.26元，所有者权益为8,153,811,730.26元；2025年度营业收入58,168,636,893.30元，归属于母公司所有者的净利润608,522,401.14元。本次增资旨在满足业务发展资金需求，优化流动性、提升财务风险抵御能力，增强<span>综合</span><span></span>竞争力，不改变公司对广州医药的实际控制权。目前该事项尚处于预披露阶段，未签署交易合同，亦无履约安排，最终是否实施存在不确定性。</p><p>（文章来源：南方财经网）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>白云山：附属公司广州医药拟增资扩股募集10亿至30亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n白云山：附属公司广州医药拟增资扩股募集10亿至30亿元\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　南财智讯7月10日电，<span><a href=\"https://laohu8.com/S/600332\">白云山</a></span>（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。广州医药为公司持股90.92%的非全资附属公司，截至2026年3月31日，资产总额为41,232,941,749.26元，所有者权益为8,153,811,730.26元；2025年度营业收入58,168,636,893.30元，归属于母公司所有者的净利润608,522,401.14元。本次增资旨在满足业务发展资金需求，优化流动性、提升财务风险抵御能力，增强<span>综合</span><span></span>竞争力，不改变公司对广州医药的实际控制权。目前该事项尚处于预披露阶段，未签署交易合同，亦无履约安排，最终是否实施存在不确定性。</p><p>（文章来源：南方财经网）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202607103801991293.html\">南方财经网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607103801991293.html","article_id":"2650184133","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650184133","pubTimestamp":1783679893,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯7月10日电，白云山（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","600332":"白云山","BK1521":"挪威政府全球养老基金持仓","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","00874":"白云山","BK1191":"制药","BK1161":"生物科技","BK0175":"白马股","BK1515":"抗疫概念","BK0070":"员工持股","BK1606":"中医药概念","BK0196":"行业龙头","BK1574":"生物医药B类股","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","09939":"开拓药业-B","BK0096":"民营医院"},"translate_title":"Baiyunshan: Subsidiary Guangzhou Pharmaceutical intends to increase capital and share expansion to raise 1 billion to 3 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"600332":1.5,"00874":1.5,"09939":1.5},"content_text":"南财智讯7月10日电，白云山（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。广州医药为公司持股90.92%的非全资附属公司，截至2026年3月31日，资产总额为41,232,941,749.26元，所有者权益为8,153,811,730.26元；2025年度营业收入58,168,636,893.30元，归属于母公司所有者的净利润608,522,401.14元。本次增资旨在满足业务发展资金需求，优化流动性、提升财务风险抵御能力，增强综合竞争力，不改变公司对广州医药的实际控制权。目前该事项尚处于预披露阶段，未签署交易合同，亦无履约安排，最终是否实施存在不确定性。（文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650184133","isCrawlerRequest":true}